AstraZeneca has had a setback in its late-stage oncology pipeline, after AKT inhibitor ceralasertib, given in combination with cancer immunotherapy Imfinzi, failed to extend survival in a lung cancer ...

This story originally published in the digital edition of Outdoor Life in 2022. On hillside a half mile below us, three rams graze on lush, green grass. A few hundred yards to our left, four young ...